Adjunctive levetiracetam treatment in pediatric lennox-gastaut syndrome

Hyo Jeong Kim, Shin Hye Kim, hoonchul kang, Joon Soo Lee, Hee Jung Chung, HeungDong Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Methods The study was an open-label, multicenter, observational clinical trial of levetiracetam as an add-on treatment in Lennox-Gastaut syndrome. Fifty-five patients aged 1.1-18.6 years (mean, 10.0 years) were enrolled. The study included a 4-8-week titration period and an 8-week maintenance period. The maintenance dose of levetiracetam was 20-80 mg/kg/day, according to its effectiveness and tolerability. The primary end point was reduction in seizure frequency, and related variables were also evaluated.

Results Among 55 patents, 51 patients (92.7%) completed the study. Thirty-two patients (58.2%) experienced a more than 50% reduction in seizure frequency, and 15 patients (27.3%) became seizure free. A reduction in seizure frequency of more than 50% was observed in 21 of 36 patients (58.3%) with convulsive seizures, 7 of 12 patients (58.3%) with drop attacks, 2 of 4 patients (50.0%) with myoclonic seizures, and 2 of 3 patients (66.7%) with epileptic spasms. Overall, 34.5% of patients reported adverse events. None of the adverse events were life threatening, and the most common adverse event was hyperactivity (12.7%).

Conclusions This study suggests that levetiracetam is a safe and effective treatment in pediatric patients with Lennox-Gastaut syndrome.

Background Our aim was to investigate the efficacy and tolerability of levetiracetam as an add-on treatment in pediatric patients with Lennox-Gastaut syndrome.

Original languageEnglish
Pages (from-to)527-531
Number of pages5
JournalPediatric Neurology
Volume51
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

etiracetam
Pediatrics
Seizures
Therapeutics
Lennox Gastaut Syndrome

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Kim, Hyo Jeong ; Kim, Shin Hye ; kang, hoonchul ; Lee, Joon Soo ; Chung, Hee Jung ; Kim, HeungDong. / Adjunctive levetiracetam treatment in pediatric lennox-gastaut syndrome. In: Pediatric Neurology. 2014 ; Vol. 51, No. 4. pp. 527-531.
@article{213a612ccc844a638f726531fda32669,
title = "Adjunctive levetiracetam treatment in pediatric lennox-gastaut syndrome",
abstract = "Methods The study was an open-label, multicenter, observational clinical trial of levetiracetam as an add-on treatment in Lennox-Gastaut syndrome. Fifty-five patients aged 1.1-18.6 years (mean, 10.0 years) were enrolled. The study included a 4-8-week titration period and an 8-week maintenance period. The maintenance dose of levetiracetam was 20-80 mg/kg/day, according to its effectiveness and tolerability. The primary end point was reduction in seizure frequency, and related variables were also evaluated.Results Among 55 patents, 51 patients (92.7{\%}) completed the study. Thirty-two patients (58.2{\%}) experienced a more than 50{\%} reduction in seizure frequency, and 15 patients (27.3{\%}) became seizure free. A reduction in seizure frequency of more than 50{\%} was observed in 21 of 36 patients (58.3{\%}) with convulsive seizures, 7 of 12 patients (58.3{\%}) with drop attacks, 2 of 4 patients (50.0{\%}) with myoclonic seizures, and 2 of 3 patients (66.7{\%}) with epileptic spasms. Overall, 34.5{\%} of patients reported adverse events. None of the adverse events were life threatening, and the most common adverse event was hyperactivity (12.7{\%}).Conclusions This study suggests that levetiracetam is a safe and effective treatment in pediatric patients with Lennox-Gastaut syndrome.Background Our aim was to investigate the efficacy and tolerability of levetiracetam as an add-on treatment in pediatric patients with Lennox-Gastaut syndrome.",
author = "Kim, {Hyo Jeong} and Kim, {Shin Hye} and hoonchul kang and Lee, {Joon Soo} and Chung, {Hee Jung} and HeungDong Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.pediatrneurol.2014.06.004",
language = "English",
volume = "51",
pages = "527--531",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "4",

}

Adjunctive levetiracetam treatment in pediatric lennox-gastaut syndrome. / Kim, Hyo Jeong; Kim, Shin Hye; kang, hoonchul; Lee, Joon Soo; Chung, Hee Jung; Kim, HeungDong.

In: Pediatric Neurology, Vol. 51, No. 4, 01.01.2014, p. 527-531.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjunctive levetiracetam treatment in pediatric lennox-gastaut syndrome

AU - Kim, Hyo Jeong

AU - Kim, Shin Hye

AU - kang, hoonchul

AU - Lee, Joon Soo

AU - Chung, Hee Jung

AU - Kim, HeungDong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Methods The study was an open-label, multicenter, observational clinical trial of levetiracetam as an add-on treatment in Lennox-Gastaut syndrome. Fifty-five patients aged 1.1-18.6 years (mean, 10.0 years) were enrolled. The study included a 4-8-week titration period and an 8-week maintenance period. The maintenance dose of levetiracetam was 20-80 mg/kg/day, according to its effectiveness and tolerability. The primary end point was reduction in seizure frequency, and related variables were also evaluated.Results Among 55 patents, 51 patients (92.7%) completed the study. Thirty-two patients (58.2%) experienced a more than 50% reduction in seizure frequency, and 15 patients (27.3%) became seizure free. A reduction in seizure frequency of more than 50% was observed in 21 of 36 patients (58.3%) with convulsive seizures, 7 of 12 patients (58.3%) with drop attacks, 2 of 4 patients (50.0%) with myoclonic seizures, and 2 of 3 patients (66.7%) with epileptic spasms. Overall, 34.5% of patients reported adverse events. None of the adverse events were life threatening, and the most common adverse event was hyperactivity (12.7%).Conclusions This study suggests that levetiracetam is a safe and effective treatment in pediatric patients with Lennox-Gastaut syndrome.Background Our aim was to investigate the efficacy and tolerability of levetiracetam as an add-on treatment in pediatric patients with Lennox-Gastaut syndrome.

AB - Methods The study was an open-label, multicenter, observational clinical trial of levetiracetam as an add-on treatment in Lennox-Gastaut syndrome. Fifty-five patients aged 1.1-18.6 years (mean, 10.0 years) were enrolled. The study included a 4-8-week titration period and an 8-week maintenance period. The maintenance dose of levetiracetam was 20-80 mg/kg/day, according to its effectiveness and tolerability. The primary end point was reduction in seizure frequency, and related variables were also evaluated.Results Among 55 patents, 51 patients (92.7%) completed the study. Thirty-two patients (58.2%) experienced a more than 50% reduction in seizure frequency, and 15 patients (27.3%) became seizure free. A reduction in seizure frequency of more than 50% was observed in 21 of 36 patients (58.3%) with convulsive seizures, 7 of 12 patients (58.3%) with drop attacks, 2 of 4 patients (50.0%) with myoclonic seizures, and 2 of 3 patients (66.7%) with epileptic spasms. Overall, 34.5% of patients reported adverse events. None of the adverse events were life threatening, and the most common adverse event was hyperactivity (12.7%).Conclusions This study suggests that levetiracetam is a safe and effective treatment in pediatric patients with Lennox-Gastaut syndrome.Background Our aim was to investigate the efficacy and tolerability of levetiracetam as an add-on treatment in pediatric patients with Lennox-Gastaut syndrome.

UR - http://www.scopus.com/inward/record.url?scp=84908123994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908123994&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2014.06.004

DO - 10.1016/j.pediatrneurol.2014.06.004

M3 - Article

C2 - 25266616

AN - SCOPUS:84908123994

VL - 51

SP - 527

EP - 531

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 4

ER -